logo
Share SHARE
FONT-SIZE Plus   Neg

Genzyme, Veracyte Announce U.S. Availability Of Afirma Thyroid FNA Analysis

Genzyme, a Sanofi company (SNY: Quote), and Veracyte, Inc.,said Monday that the Afirma Thyroid FNA Analysis, an innovative approach for improved thyroid nodule diagnosis, is now available to patients across the United States.

The Afirma Thyroid FNA Analysis combines expert cytopathology assessment of thyroid nodule fine needle aspiration samples, with the Afirma Gene Expression Classifier, a novel genomic test, used to resolve inconclusive results and thus help patients whose nodules are actually benign avoid unnecessary surgery.

Two independent clinical studies to date have shown that the Afirma Gene Expression Classifier can reclassify patients with indeterminate thyroid FNA results as "benign" with the same degree of accuracy as a benign cytopathology diagnosis.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Automakers on Friday reported higher U.S. vehicle sales for the month of April, helped by low gasoline prices as well as continuing strong demand for trucks and utility vehicles. General Motors Co. and FCA US, LLC each reported sales growth of about 6% for the month, while Ford Motor Co. and Toyota Motor Corp. reported 5.4% and 1.8% increases, respectively. Are you really ready for an objective appraisal of how old you look? If not, stay far away from How-Old.net, a website to guess how old you are, which was introduced at the recent Microsoft Build 2015 developer conference. The website has caught... LinkedIn Corp., the world's largest online professional network, said Thursday after the markets closed that its first quarter loss widened from last year, as higher costs and expenses more than offset a 35% increase in revenue. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations as did its quarterly revenue.
comments powered by Disqus
RELATED NEWS
Trade SNY now with 
Follow RTT